| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ahmad A Khundakar, Alan J Thoma. Neuropathology of depression in Alzheimer's disease: current knowledge and the potential for new treatments. Journal of Alzheimer's disease : JAD. vol 44. issue 1. 2015-09-10. PMID:25208623. |
postmortem studies have also suggested that depression in dementia does not arise from serotonergic or noradrenergic abnormalities, or indeed from the degenerative pathology associated with alzheimer's disease. |
2015-09-10 |
2023-08-13 |
Not clear |
| Christophe Rochais, Cédric Lecoutey, Florence Gaven, Patrizia Giannoni, Katia Hamidouche, Damien Hedou, Emmanuelle Dubost, David Genest, Samir Yahiaoui, Thomas Freret, Valentine Bouet, François Dauphin, Jana Sopkova de Oliveira Santos, Céline Ballandonne, Sophie Corvaisier, Aurélie Malzert-Fréon, Remi Legay, Michel Boulouard, Sylvie Claeysen, Patrick Dallemagn. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. Journal of medicinal chemistry. vol 58. issue 7. 2015-06-30. PMID:25793650. |
novel multitarget-directed ligands (mtdls) with acetylcholinesterase (ache) inhibitory and serotonergic subtype 4 receptor (5-ht4r) agonist activities as potential agents against alzheimer's disease: the design of donecopride. |
2015-06-30 |
2023-08-13 |
mouse |
| Maria J Ramirez, Mitchell K P Lai, Rosa M Tordera, Paul T Franci. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs. vol 74. issue 7. 2015-05-25. PMID:24802806. |
serotonergic therapies for cognitive symptoms in alzheimer's disease: rationale and current status. |
2015-05-25 |
2023-08-13 |
Not clear |
| In Ho Jung, Hyung Eun Lee, Se Jin Park, Young Je Ahn, Guyoung Kwon, Hyun Woo, So Young Lee, Ju Sun Kim, Yeong-Woo Jo, Dae Sik Jang, Sam Sik Kang, Jong Hoon Ry. Ameliorating effect of spinosin, a C-glycoside flavonoid, on scopolamine-induced memory impairment in mice. Pharmacology, biochemistry, and behavior. vol 120. 2014-12-09. PMID:24582850. |
taken together, these results indicate that the memory-ameliorating effect of spinosin may be, in part, due to the serotonergic neurotransmitter system, and that spinosin may be useful for the treatment of cognitive dysfunction in diseases such as alzheimer's disease. |
2014-12-09 |
2023-08-12 |
mouse |
| Mohammad Seyedabadi, Gohar Fakhfouri, Vahid Ramezani, Shahram Ejtemaei Mehr, Reza Rahimia. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Experimental brain research. vol 232. issue 3. 2014-10-14. PMID:24430027. |
in addition, there has been an alteration in the density of serotonergic receptors in aging and alzheimer's disease, and serotonin modulators are found to alter the process of amyloidogenesis and exert cognitive-enhancing properties. |
2014-10-14 |
2023-08-12 |
Not clear |
| Sebastiaan Engelborghs, Kristel Sleegers, Stefan Van der Mussele, Nathalie Le Bastard, Nathalie Brouwers, Christine Van Broeckhoven, Peter Paul De Dey. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 35. issue 1. 2013-12-27. PMID:23334703. |
a prospective, longitudinal study was set up to investigate possible genetic associations of behavioral and psychological signs and symptoms of dementia (bpsd) in alzheimer's disease (ad) with two candidate genes in the serotonergic neurotransmitter pathway: serotonin transporter (slc6a4) and brain-specific tryptophan hydroxylase (tph2). |
2013-12-27 |
2023-08-12 |
Not clear |
| José Julio Rodríguez, Harun N Noristani, Alexei Verkhratsk. The serotonergic system in ageing and Alzheimer's disease. Progress in neurobiology. vol 99. issue 1. 2013-07-10. PMID:22766041. |
the serotonergic system in ageing and alzheimer's disease. |
2013-07-10 |
2023-08-12 |
Not clear |
| Agnes Fehér, Anna Juhász, Anna László, Magdolna Pákáski, János Kálmán, Zoltán Jank. Serotonin transporter and serotonin receptor 2A gene polymorphisms in Alzheimer's disease. Neuroscience letters. vol 534. 2013-06-18. PMID:23274704. |
genetic variants of the serotonergic neurotransmitter system are potential contributing factors in the pathological processes underlying alzheimer's disease (ad). |
2013-06-18 |
2023-08-12 |
Not clear |
| Markus Savli, Andreas Bauer, Markus Mitterhauser, Yu-Shin Ding, Andreas Hahn, Tina Kroll, Alexander Neumeister, Daniela Haeusler, Johanna Ungersboeck, Shannan Henry, Sanaz Attaripour Isfahani, Frank Rattay, Wolfgang Wadsak, Siegfried Kasper, Rupert Lanzenberge. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage. vol 63. issue 1. 2013-01-29. PMID:22789740. |
the highly diverse serotonergic system with at least 16 different receptor subtypes is implicated in the pathophysiology of most neuropsychiatric disorders including affective and anxiety disorders, obsessive compulsive disorder, post-traumatic stress disorder, eating disorders, sleep disturbance, attention deficit/hyperactivity disorder, drug addiction, suicidal behavior, schizophrenia, alzheimer, etc. |
2013-01-29 |
2023-08-12 |
human |
| Lisbeth Marner, Vibe G Frokjaer, Jan Kalbitzer, Szabolcs Lehel, Karine Madsen, William F C Baaré, Gitte M Knudsen, Steen G Hasselbalc. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiology of aging. vol 33. issue 3. 2012-09-28. PMID:20510480. |
loss of serotonin 2a receptors exceeds loss of serotonergic projections in early alzheimer's disease: a combined [11c]dasb and [18f]altanserin-pet study. |
2012-09-28 |
2023-08-12 |
human |
| Lisbeth Marne. Communication among neurons. Danish medical journal. vol 59. issue 4. 2012-08-02. PMID:22459725. |
furthermore, a pet study of patients with alzheimer's disease with the serotonin transporter ligand [11c]dasb showed relatively preserved serotonergic projections, despite a marked decrease in 5-ht2a receptor binding. |
2012-08-02 |
2023-08-12 |
human |
| H N Noristani, R S Meadows, M Olabarria, A Verkhratsky, J J Rodrígue. Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study. Cell death & disease. vol 2. 2011-11-28. PMID:21918544. |
increased hippocampal ca1 density of serotonergic terminals in a triple transgenic mouse model of alzheimer's disease: an ultrastructural study. |
2011-11-28 |
2023-08-12 |
mouse |
| Cristina Lorenzi, Alessandra Marcone, Adele Pirovano, Elena Marino, Francesco Cordici, Chiara Cerami, Dario Delmonte, Stefano F Cappa, Placido Bramanti, Enrico Smerald. Serotonin transporter and saitohin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: preliminary findings. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 31. issue 6. 2011-09-28. PMID:20852909. |
serotonergic transmission impairment and abnormal phosphorylation of tau protein have been implicated in the physiopathology of alzheimer's disease (ad) and frontotemporal lobar dementia (ftld). |
2011-09-28 |
2023-08-12 |
human |
| Lee A Shapiro, Lynn A Bialowas-McGoey, Patricia M Whitaker-Azmiti. Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model. Cardiovascular psychiatry and neurology. vol 2010. 2011-07-14. PMID:20827311. |
effects of s100b on serotonergic plasticity and neuroinflammation in the hippocampus in down syndrome and alzheimer's disease: studies in an s100b overexpressing mouse model. |
2011-07-14 |
2023-08-12 |
mouse |
| Mitchell K P Lai, Shirley W Tsang, Margaret M Esiri, Paul T Francis, Peter T-H Wong, Christopher P Che. Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. Psychopharmacology. vol 213. issue 2-3. 2011-05-24. PMID:20625884. |
previous studies have shown extensive serotonergic deficits in the hippocampus of alzheimer's disease (ad) patients. |
2011-05-24 |
2023-08-12 |
Not clear |
| H Muck. KA-672 Dr Wilmar Schwabe GmbH & Co. IDrugs : the investigational drugs journal. vol 1. issue 1. 2010-06-09. PMID:18465518. |
ka-672 dr wilmar schwabe gmbh & co. ka-672 is a multifunctional antidementia agent under development by schwabe as a potential agent to combat cognitive and other symptoms of alzheimer's disease (ad), via modulation of the interplay between serotonergic, adrenergic, dopaminergic and cholinergic systems [260590]. |
2010-06-09 |
2023-08-12 |
Not clear |
| Seethalakshmi Ramanathan, Stephen J Glat. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 17. issue 10. 2010-01-28. PMID:19910872. |
serotonergic system genes in psychosis of alzheimer dementia: meta-analysis. |
2010-01-28 |
2023-08-12 |
Not clear |
| Francesco Angelucci, Sergio Bernardini, Paolo Gravina, Lorenza Bellincampi, Alberto Trequattrini, Fulvia Di Iulio, Diego Vanni, Giorgio Federici, Carlo Caltagirone, Paola Bossù, Gianfranco Spallett. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. Journal of Alzheimer's disease : JAD. vol 17. issue 1. 2009-08-12. PMID:19494443. |
although the etiology of psychotic symptoms (hallucinations and delusions) in alzheimer's disease is still not known, alterations in serotonergic neurotransmission have been proposed. |
2009-08-12 |
2023-08-12 |
Not clear |
| Laura Kenton, Francis Boon, Donald P Cai. Combined but not individual administration of beta-adrenergic and serotonergic antagonists impairs water maze acquisition in the rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 6. 2008-08-07. PMID:17653108. |
the data imply that (1) serotonergic and beta-adrenergic systems may interact in a manner that is important for adaptive behavior; (2) impairments in these systems found in alzheimer patients may be important for their cognitive and behavioral impairments; and (3) the approach used here can model aspects of the cognitive and behavioral impairments in alzheimer disease. |
2008-08-07 |
2023-08-12 |
rat |
| Sabina Pappatà, Elena Salvatore, Alfredo Postiglion. In vivo imaging of neurotransmission and brain receptors in dementia. Journal of neuroimaging : official journal of the American Society of Neuroimaging. vol 18. issue 2. 2008-06-17. PMID:18380693. |
these methods have been applied over the last years to explore the integrity of cholinergic, serotonergic, gabaergic, and dopaminergic systems in alzheimer's disease (ad) and in other dementias. |
2008-06-17 |
2023-08-12 |
human |